BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31811110)

  • 1. Interplay of MKP-1 and Nrf2 drives tumor growth and drug resistance in non-small cell lung cancer.
    Wang H; Liu K; Chi Z; Zhou X; Ren G; Zhou R; Li Y; Tang X; Wang XJ
    Aging (Albany NY); 2019 Dec; 11(23):11329-11346. PubMed ID: 31811110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
    Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
    Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mkp-1 protects mice against toxin-induced liver damage by promoting the Nrf2 cytoprotective response.
    Luo L; Chen Y; Wang H; Wang S; Liu K; Li X; Wang XJ; Tang X
    Free Radic Biol Med; 2018 Feb; 115():361-370. PubMed ID: 29241671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory role of KEAP1 and NRF2 in PPARĪ³ expression and chemoresistance in human non-small-cell lung carcinoma cells.
    Zhan L; Zhang H; Zhang Q; Woods CG; Chen Y; Xue P; Dong J; Tokar EJ; Xu Y; Hou Y; Fu J; Yarborough K; Wang A; Qu W; Waalkes MP; Andersen ME; Pi J
    Free Radic Biol Med; 2012 Aug; 53(4):758-68. PubMed ID: 22684020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer.
    Singh A; Misra V; Thimmulappa RK; Lee H; Ames S; Hoque MO; Herman JG; Baylin SB; Sidransky D; Gabrielson E; Brock MV; Biswal S
    PLoS Med; 2006 Oct; 3(10):e420. PubMed ID: 17020408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteolin inhibits the Nrf2 signaling pathway and tumor growth in vivo.
    Chian S; Thapa R; Chi Z; Wang XJ; Tang X
    Biochem Biophys Res Commun; 2014 May; 447(4):602-8. PubMed ID: 24747074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
    Chian S; Zhao Y; Xu M; Yu X; Ke X; Gao R; Yin L
    Anticancer Drugs; 2019 Sep; 30(8):838-845. PubMed ID: 31415285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The investigation of mitogen-activated protein kinase phosphatase-1 as a potential pharmacological target in non-small cell lung carcinomas, assisted by non-invasive molecular imaging.
    Tai CJ; Wu AT; Chiou JF; Jan HJ; Wei HJ; Hsu CH; Lin CT; Chiu WT; Wu CW; Lee HM; Deng WP
    BMC Cancer; 2010 Mar; 10():95. PubMed ID: 20226009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNAi-mediated silencing of nuclear factor erythroid-2-related factor 2 gene expression in non-small cell lung cancer inhibits tumor growth and increases efficacy of chemotherapy.
    Singh A; Boldin-Adamsky S; Thimmulappa RK; Rath SK; Ashush H; Coulter J; Blackford A; Goodman SN; Bunz F; Watson WH; Gabrielson E; Feinstein E; Biswal S
    Cancer Res; 2008 Oct; 68(19):7975-84. PubMed ID: 18829555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docosahexaenoic acid induces apoptosis in lung cancer cells by increasing MKP-1 and down-regulating p-ERK1/2 and p-p38 expression.
    Serini S; Trombino S; Oliva F; Piccioni E; Monego G; Resci F; Boninsegna A; Picci N; Ranelletti FO; Calviello G
    Apoptosis; 2008 Sep; 13(9):1172-83. PubMed ID: 18679798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mkp-1 cross-talks with Nrf2/Ho-1 pathway protecting against intestinal inflammation.
    Li J; Wang H; Zheng Z; Luo L; Wang P; Liu K; Namani A; Jiang Z; Wang XJ; Tang X
    Free Radic Biol Med; 2018 Aug; 124():541-549. PubMed ID: 30061089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Nrf2 Pathway Inhibitor Sensitizes Keap1-Mutant Lung Cancer Cells to Chemotherapy.
    Zhang D; Hou Z; Aldrich KE; Lockwood L; Odom AL; Liby KT
    Mol Cancer Ther; 2021 Sep; 20(9):1692-1701. PubMed ID: 34158350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mkp-1 is required for chemopreventive activity of butylated hydroxyanisole and resveratrol against colitis-associated colon tumorigenesis.
    Zheng Z; Chen Y; Huang J; Deng H; Tang X; Wang XJ
    Food Chem Toxicol; 2019 May; 127():72-80. PubMed ID: 30844440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitogen-activated protein kinase phosphatase-1 is required for cisplatin resistance.
    Wang Z; Xu J; Zhou JY; Liu Y; Wu GS
    Cancer Res; 2006 Sep; 66(17):8870-7. PubMed ID: 16951204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Keap1-Nrf2 Interaction Suppresses Cell Motility in Lung Adenocarcinomas by Targeting the S100P Protein.
    Chien MH; Lee WJ; Hsieh FK; Li CF; Cheng TY; Wang MY; Chen JS; Chow JM; Jan YH; Hsiao M; Hua KT; Kuo ML
    Clin Cancer Res; 2015 Oct; 21(20):4719-32. PubMed ID: 26078391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
    Leone A; Roca MS; Ciardiello C; Terranova-Barberio M; Vitagliano C; Ciliberto G; Mancini R; Di Gennaro E; Bruzzese F; Budillon A
    Free Radic Biol Med; 2015 Dec; 89():287-99. PubMed ID: 26409771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin Sensitizes Non-small Cell Lung Cancer Cells to an Epigallocatechin-3-Gallate (EGCG) Treatment by Suppressing the Nrf2/HO-1 Signaling Pathway.
    Yu C; Jiao Y; Xue J; Zhang Q; Yang H; Xing L; Chen G; Wu J; Zhang S; Zhu W; Cao J
    Int J Biol Sci; 2017; 13(12):1560-1569. PubMed ID: 29230104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
    Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
    Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone acetylranseferase hMOF acetylates Nrf2 and regulates anti-drug responses in human non-small cell lung cancer.
    Chen Z; Ye X; Tang N; Shen S; Li Z; Niu X; Lu S; Xu L
    Br J Pharmacol; 2014 Jul; 171(13):3196-211. PubMed ID: 24571482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.